Friederike Herbst

机构：Parker Institute for Cancer Immunotherapy, University of Pennsylvania · ORCID：0000-0002-2167-750X

发表论文 168 篇 · 总被引 1730 次 · h-index 19

代表论文

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies (2025 · Nature Medicine · 被引 78)
TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function (2024 · Science Advances · 被引 34)
Lipid nanoparticle-mediated epitope editing in human HSPCs enables resistance to CD45-directed CAR-T cell therapy (2025 · Blood · 被引 1)
Expansion of human hematopoietic stem cells by inhibiting translation (2025 · Blood · 被引 1)
A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection (2026 · Journal of Hematology & Oncology)
Figure S11 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction (2025)